CRISPR Therapeutics CRSP

HealthcareMarket cap $4B7 connections

CRISPR Therapeutics (with Vertex) got the first CRISPR gene editing therapy approved - Casgevy, which functionally cures sickle cell disease. This is one of the most significant medical milestones in history. CRISPR's pipeline targets beta-thalassemia, cancer immunotherapy, and type 1 diabetes.

Explore CRISPR Therapeutics on the interactive map Relationship timeline Find a path to another company

Suppliers 1

Companies that sell to CRISPR Therapeutics

IlluminaHealthcare · $20BIllumina sequencing for CRISPR gene validation

Partners 5

Strategic partnerships, joint products and alliances

Vertex PharmaHealthcare · $120BCRISPR Therapeutics co-developer with Vertex
Sarepta TherapeuticsHealthcare · $10BCompeting DMD gene therapy approaches
Beam TherapeuticsHealthcare · $2BCompeting next-gen gene editing modalities
Intellia TherapeuticsHealthcare · $2BIntellia and CRISPR Therapeutics both in-vivo CRISPR
Editas MedicineHealthcare · $1BEditas and CRISPR Therapeutics competing CRISPR IP

Competitors 1

Companies it competes with

ModernaHealthcare · $45BGene therapy market

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show CRISPR Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=CRSP" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="CRISPR Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.